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Psoriasis (Pso) is a common chronic cutaneous inflammatory disease involving the skin that
is associated with serious comorbidities. Comorbidities in Pso include psoriatic arthritis
(PsA), reduced quality of life, malignancy, depression, but also a constellation of associ-
ated conditions that enhance the cardiovascular (CV) risk. Indeed, obesity is common in
patients with Pso or PsA and is considered to be a risk factor for the onset of these dis-
eases. Patients with Pso and PsA share common obesity-related complications such as
metabolic syndrome (MetS), dyslipidemia, diabetes or insulin resistance, and CV diseases.
Chronic inflammation in Pso and PsA partially explains the development of atherosclerosis
and CV diseases. In parallel, body composition is disturbed in patients with Pso or PsA,
as suggested by anthropometric measurements, while an excess of abdominal adiposity
is observed in PsA, enhancing the risk of MetS and CV diseases. Adipokines may link
the adipose tissue to the obesity-related complications of Pso and PsA. Indeed, altered
circulating levels of the adipokines leptin, adiponectin, visfatine, and resistin have been
found in patients with Pso or PsA. In addition, an excess of adipose tissue may compro-
mise the therapeutic response to traditional drugs or biological agents in Pso and PsA.This
paper reviews the comorbidities that contribute to enhanced CV risk, the body composi-
tion results, and the potential role of adipokines in systemic inflammation and energetic
balance in Pso and PsA.
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INTRODUCTION
Psoriasis (Pso) is a chronic cutaneous immune-mediated disease
that affects around 1–3% of the adult population in Europe and
North America. Its pathophysiology involves genetic and envi-
ronmental factors together with immune disturbances. Pso is a
papulosquamous disease with variable morphology, distribution,
severity, and course. Cutaneous lesions are characterized by very
well circumscribed scaling papules and plaques that are typically
distributed symmetrically on the knees, elbows, scalp, genitals, and
trunk (1). Different clinical forms of Pso are described including
plaque Pso, guttate Pso, nail Pso, Pso inversa, localized and gener-
alized pustular forms, and erythrodermic Pso. There is substantial
evidence demonstrating that Pso is associated with various comor-
bidities, such as depression, cancer, obesity, and cardiovascular
(CV) diseases (2). Indeed, an increased risk of coronary, cere-
brovascular, and peripheral vascular diseases has been reported in
patients with severe Pso (2).
Another common comorbidity in Pso is psoriatic arthritis
(PsA), an inflammatory arthritic condition (3). The prevalence of
PsA is estimated at between 6 and 40% in the psoriatic population.
PsA is classified in the spondyloarthritis group and is commonly
characterized by synovitis, enthesitis, dactylitis, and spondylitis.
Typically, the skin disease occurs before the onset of arthritis in
more than 80% of patients. Nail dystrophy, Pso of the scalp, and/or
intergluteal/perianal Pso have been identified as clinical predictors
for the development of arthritis (4). PsA is currently diagnosed
using the ClASsification for Psoriatic ARthritis (CASPAR) crite-
ria, with the requirement of established inflammatory articular
disease plus at least three points from the following: current Pso
(assigned a score of 2; all other features assigned a score of 1), a
history of Pso, a family history of Pso, dactylitis, juxta-articular
new bone formation, negative rheumatoid factor, and nail dystro-
phy (5). These criteria are highly specific and sensitive. The clinical
presentation of PsA can manifest as peripheral arthritis, asymmet-
rical oligoarthritis, arthritis mutilans, or ankylosing spondylitis.
The severity of PsA is variable, ranging from mild to severely
debilitating disease with joint damage and functional impairment
(3). PsA may also manifest as extra-articular disease with anterior
uveitis and various comorbidities including depression, obesity,
metabolic syndrome (MetS), and CV disease (6).
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The pathogenesis of Pso and PsA includes common pathways
with the implication of Th1, Th17, and Th22-mediated inflam-
mation, inducing the production of pro-inflammatory cytokines
such as Il-17 and TNFα (1, 3). Therapeutic management tar-
geting TNFα and IL-23 (TNFα inhibitors and ustekinumab, an
anti-IL12/23 p40 monoclonal antibody, respectively) has been
proven to be highly effective in both Pso and PsA (7). In par-
allel to these common pathophysiological mechanisms, Pso and
PsA also share common predisposing factors and/or comorbidi-
ties, especially obesity and related metabolic complications, as well
as a higher risk of CV disease (6, 8). Obesity is characterized by
chronic low grade inflammation and is considered to promote a
low grade inflammatory state. Adipose tissue is in fact an active
organ responsible for the production of a wide range of proteins
or adipokines that have diverse physiological functions, including
involvement in chronic inflammation (9).
In this review, we aim to discuss the role and influence of
adipose tissue on Pso and PsA, adipokines, and body compo-
sition changes in these patient populations. The pattern of CV
comorbidity in Pso and PsA as well as the influence of obesity on
therapeutic response are also described.
CARDIOVASCULAR RISK FACTORS AND COMORBIDITIES IN
PSORIASIS AND PSORIATIC ARTHRITIS
There is a constellation of comorbid conditions that are expe-
rienced by patients with Pso, with a predominance of CV and
metabolic diseases (2). A modest increase in lymphoma including
Hodgkin’s and cutaneous T cell lymphoma have been reported
in patients with Pso in a large controlled cohort study (10).
Solid organ malignancies (liver, pancreas, lung, breast, kidney)
also occur in Pso with an increased risk. The use of psoralen
ultraviolet and cyclosporin have been proposed as predisposing
factors for the development of these malignancies (11). Impaired
quality of life and depression are also frequent in patients with
Pso (2). However, the main comorbidity in patients with Pso
concerns CV involvement. In fact, there are a number of epi-
demiological studies in Pso demonstrating a high prevalence of
CV diseases, including myocardial infarction, cerebrovascular dis-
eases, and peripheral vascular diseases (12–14). Traditional CV
risk factors are also commonly observed with a high frequency in
patients with Pso, contributing to the CV burden. Among these
factors are MetS, diabetes mellitus, insulin resistance, hyperten-
sion, dyslipidemia, and smoking (15–17). The MetS is defined
by the presence of three or more features among the following:
abdominal obesity, insulin resistance, decreased HDL cholesterol,
hypertriglyceridemia, and hypertension (18). There are a substan-
tial number of studies demonstrating that patients with Pso have
these components of the MetS, largely contributing to their CV
risk (2, 15). Hypertension is more often observed in patients with
Pso as compared to a control population, although this associa-
tion remains controversial (2). Pso is associated with dyslipidemia
with higher concentrations of triglycerides, total cholesterol, and
LDL cholesterol (16). Increased prevalence of type 2 diabetes is
observed in Pso, with a significant correlation between the dura-
tion of Pso and glucose intolerance (17). CV diseases and related
mortality have been reported in patients with severe Pso both
in cohort and population-based studies. Overall, these studies
show an increased risk of various CV diseases, such as myocardial
infarction, stroke, and peripheral vascular disease (2). A recent
systematic literature review of CV morbidity and mortality in Pso
identified 33 observational studies in patients with Pso and PsA
and found an increased risk of myocardial infarction in Pso with an
odds ratio (OR) of 1.25 (95% CI: 1.03–1.52), compared to the gen-
eral population (19). This risk was more elevated in patients with
severe skin disease and early onset. An association was also found
between Pso and coronary artery disease, with an OR ranging from
1.19 to 1.80 according to the design of the studies. On the con-
trary, the increase in the risk of stroke was less pronounced, with a
slightly higher risk (OR: 1.14, 95% CI: 1.08–1.99). In this system-
atic review, peripheral artery disease was found to be associated
with Pso, but the limited number of studies precluded estimation
of the OR.
Psoriatic arthritis is also associated with various comorbidities,
including depression, obesity, MetS, hypertension, and premature
CV disease (6, 20, 21). The association between PsA, CV diseases,
and comorbidities is complex and not well understood. In fact,
in terms of CV risk, several studies have demonstrated a higher
risk in patients with Pso but data on CV disease more specif-
ically in PsA are limited. Theoretically, the coexistence of skin
disease with arthritis in patients with PsA may be responsible for
a greater inflammatory load and consequently, these patients may
be more prone to developing CV disease compared to patients
with only skin involvement. A systematic literature search analyzed
CV comorbidities and CV risk factors in patients with PsA (22).
Twenty-eight articles were selected in this analysis, which revealed
mixed results for CV mortality. Among three observational stud-
ies, two showed a higher standardized mortality rate (1.6 and
1.4, respectively) while the third did not observe an increase in
mortality rate. The same findings were observed with population-
based studies. On the contrary, results for CV disease and risk
factors were more consistent, indicating increased CV morbidity
in PsA, including ischemic heart disease, congestive heart failure,
cerebrovascular, and peripheral vascular disease. This review indi-
cated that traditional CV risk factors were commonly observed in
patients with PsA, with an increased prevalence of hypertension,
obesity, diabetes mellitus, and dyslipidemia. Indeed, hypertension
was found in 30% of all PsA patients. However, this review ana-
lyzed only data in patients with PsA without parallel assessment
of Pso patients without arthritis and no OR for the increased CV
risk was available. Conversely, a study by Husted et al. compared
CV morbidity in PsA vs. Pso without arthritis (23). This study
was performed in Canada from a cohort of Pso without arthritis
cohort and a PsA cohort. The results showed that the prevalence
of hypertension, obesity, hyperlipidemia, type 2 diabetes mellitus,
and at least one CV event was higher in patients with PsA com-
pared to Pso, with unadjusted OR ranging from 1.54 to 2.59. The
main comorbidity that remained significantly elevated in PsA after
adjustment for confounding factors was hypertension (adjusted
OR: 2.17, 95% CI: 1.22–3.83). Similarly, the literature review by
Horreau et al. compared CV morbidity and mortality in patients
with PsA and Pso compared to controls (19). An increased risk of
myocardial infarction was noted in both groups, with PsA patients
at higher risk (OR 1.57, 95% CI: 1.08–2.27 in PsA compared to
1.25, 95%, CI: 1.03–1.52 in Pso). An increased risk of coronary
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heart disease was again observed in Pso and PsA, but the lim-
ited number of studies did not allow quantification of this risk.
In addition, this analysis did not observe an increased risk of CV
mortality in patients with Pso or PsA.
OBESITY IN PSORIASIS AND PSORIATIC ARTHRITIS
A strong association between increased body weight, adiposity, and
Pso has recently emerged (8). Indeed, several studies have con-
sistently underlined a significant link between body mass index
(BMI) and Pso. A case–control study performed in Italy found an
association between BMI and Pso of recent onset, with an OR
of 1.6 (95% CI: 1.1–2.1) and 1.9 (95% CI: 1.2–2.8) for over-
weight (BMI ranging from 26 to 29 kg/m2) and obese patients
(BMI ≥30 kg/m2), respectively (24). Similarly, the prevalence of
obesity in patients with Pso was found to be twice as high as
that in the general population in the Utah Pso initiative study
(25). The relationship between BMI, weight change, and waist
circumference was examined in women included in the Nurse’s
Health study in a prospective longitudinal study over a 14 year
period. This study demonstrated a graded positive association
between BMI evaluated at multiple time points and the risk of
incident Pso. Similarly, measurements of visceral adiposity (waist
circumference, waist-to-hip ratio) and weight gain were identi-
fied as strong predictors of Pso development (26). This study
provides strong evidences that increased adiposity is a risk fac-
tor for incident Pso. Conversely, certain studies reported that BMI
increased in patients after Pso diagnosis, suggesting that obesity
is secondary to Pso (25). Whether adipose tissue is a risk factor
for Pso development or a secondary feature after its onset still
remains debated. However, cross-sectional studies have indicated
that obesity is more prevalent in patients with severe Pso than in
patients with mild disease, reinforcing the link between fat mass
and Pso (17, 27).
In parallel to its influence on Pso, obesity also plays a role
in PsA (6). Indeed, an increased prevalence of obesity has been
reported in PsA as compared to the general population. A case–
control study in patients with Pso found that BMI at age 18 years,
and not current BMI, was associated with the development of
PsA (28). A cohort study using an electronic database of medical
records and representative of the general population in the United
Kingdom analyzed the impact of the first BMI measured after
Pso diagnosis on incident PsA (29). This study found that PsA
incidence rates increased in tandem with increasing BMI: com-
pared with Pso patients with BMI <25 kg/m2, the relative risk
(RR) for developing PsA was 1.09 (95% CI: 0.93–1.28) for BMI
from 25 to 29.9 kg/m2, 1.22 (95% CI: 1.02–1.47) for BMI from 30
to 34.4 kg/m2, and 1.48 (95% CI 1.2–1.81) for BMI ≥35 kg/m2.
These results were observed both in subjects with Pso and in the
general population, independently of age, sex, trauma, smoking
status, and alcohol intake (29). Another study examined the risk
of incident PsA in US women participating in the longitudinal
Nurse’s Health II study cohort, over a 14 year period. The results
showed a strong relationship between BMI and increased inci-
dent risk of PsA: compared with BMI<25 kg/m2, the RR was 1.83
(95% CI: 1.15–2.89) for BMI from 25 to 29.9 kg/m2, 3.12 (95% CI:
1.90–5.11) for BMI from 30 to 34.9 kg/m2, and 6.64 (95% CI: 4.11–
10.16) for BMI>35 kg/m2. Moreover, there was a graded positive
association between weight changes from age 18 years, measures
of central obesity (as evaluated by waist circumference and hip to
waist ratio) and the risk of incident PsA (30). These two studies,
thus, provide evidence linking obesity to the risk of incident PsA.
In addition, the prevalence of obesity was higher in patients with
PsA compared to patients with Pso in the study by Husted et al.
(unadjusted OR: 1.58, 95% CI: 1.19–2.09) (23).
BODY COMPOSITION IN PSORIASIS AND PSORIATIC
ARTHRITIS
Data on body composition in patients with Pso or PsA are sparse.
Anthropometric measurements such as waist circumference or
waist-to-hip ratio reflect central or abdominal adiposity and have
been proposed as substantial indicators of health risk. These
indices have been recorded in patients with Pso or PsA. In the
study by Setty et al., waist circumference and waist-to-hip ratio
were associated with the risk of incident Pso (26). Similarly, these
same measures of visceral adiposity were reported to be associated
with the development of PsA (30). Children with Pso had excess
adiposity and increased central adiposity as evaluated by waist cir-
cumference and waist-to-height ratio, regardless of Pso severity
(31). Fat mass and its distribution may be more specifically eval-
uated by dual-energy X ray absorptiometry (DXA), the reference
method for body composition measurements. However, a limited
number of studies have evaluated body composition in patients
with Pso using DXA. In a series of Brazilian patients with Pso,
total body fat was similar between psoriatic patients and healthy
controls (32). In the same study, patients with PsA had more evi-
dence of adiposity with a significantly higher body fat percentage
than Pso and healthy controls. In these patients, the excess of fat
tissue was located in the android region.
ADIPOKINES IN PSORIASIS AND PSORIATIC ARTHRITIS
Adipose tissue is mainly composed of adipocytes, with, in par-
allel, a stromal–vascular fraction, which includes macrophages.
Adipocytes are able to secrete a wide range of proteins called
adipokines, which are involved in different physiologic processes.
Besides these functions, adipokines also interact with immune
cells, therefore, contributing to the inflammatory network (9). For
instance, the adipokines, such as leptin, visfatin, and resistin, dis-
play pro-inflammatory activities. On the contrary, adiponectin is
believed to have anti-inflammatory effects, especially, its low mol-
ecular weight isoform. Adipose tissue is also a substantial source of
pro-inflammatory cytokines such as IL-6, TNFα, and IL-8. In par-
allel to their relationships with the immune system, adiponectin,
visfatin, and resistin have metabolic functions and play a role in
insulin sensitivity (33). Moreover, clinical studies suggest a regula-
tory and anti-inflammatory role for adiponectin in atherosclerosis.
Thus, by affecting vascular function, immune regulation, and glu-
cose metabolism, adipokines are considered as key players in the
pathogenesis of obesity-related complications such as MetS and
CV morbidity. The role and influence of fat tissue and adipokines
is increasingly studied in chronic immune-mediated diseases, such
as chronic inflammatory skin or rheumatic diseases (9, 34). There-
fore, the assessment of fat distribution and adipokine production
is a relevant issue in conditions associated with an excess of fat,
such as Pso and PsA.
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In patients with Pso,circulating adiponectin (total adiponectin)
levels have been shown to be decreased as compared to healthy
controls (35, 36). A negative correlation between adiponectin and
extent of the skin disease evaluated by psoriasis area severity index
(PASI) or pro-inflammatory cytokines, such as IL-6 and TNFα
was found in these studies (35, 36). On the contrary, leptin levels
were increased in both male and female patients with Pso (37).
In an immunohistochemistry study, the cutaneous expression of
leptin and leptin receptor correlated with severity of Pso and dis-
ease duration (38). Similarly, resistin concentration was increased
in patients with Pso and correlated with disease severity (39). In
a gene expression study performed in peripheral blood mononu-
clear cells from patients with Pso, the visfatin gene was found
strongly up-regulated (40). Retinol-binding protein-4 (RBP-4) is
mainly produced by visceral adipose tissue and plays a major role
in insulin resistance. It has previously been demonstrated that
serum RBP-4 positively correlates with several CV risk factors, such
as BMI, waist-to-hip ratio, serum triglycerides, and systolic blood
pressure and may thus play a role in CV diseases in obese subjects
(41). In patients with Pso, surprisingly, decreased serum RBP-4
concentrations have been found compared to healthy controls
(42). Omentin is a protein produced by stromal–vascular cells of
visceral adipose tissue and it increases insulin sensitivity by stimu-
lating insulin-mediated glucose uptake in human adipocytes. Since
serum levels of omentin inversely correlate with fat mass, omentin
is regarded as a positive marker that counteracts the obese state.
Omentin serum levels were found to be decreased in patients with
Pso and negatively correlated with BMI and waist circumference,
as expected (43). A study conducted in Canada compared serum
adipokine levels between patients with PsA and patients with Pso
without arthritis. This study found that the prevalence of MetS was
higher in the PsA group (36.5 vs. 27.1%) without reaching statisti-
cal significance (p= 0.056). Serum adipokine levels were higher in
patients with PsA compared to Pso, especially, adiponectin and lep-
tin in women (44). In another study, patients with PsA had higher
serum levels of leptin and omentin but decreased adiponectin
levels compared to healthy controls (45).
INFLUENCE OF BIOLOGICAL AGENTS ON ADIPOSITY AND
INFLUENCE OF ADIPOSITY ON THE THERAPEUTIC RESPONSE
IN PSORIASIS AND PSORIATIC ARTHRITIS
We previously reported that anti-TNFα therapy given in patients
with rheumatoid arthritis (RA) or spondyloarthritis is associated
with a significant increase in body weight, BMI, fat mass, and
especially fat mass in the android region (46). Our results also
suggested that this fat mass distributed to the intra-visceral region.
This fat redistribution raises questions about its influence on the
CV profile of patients receiving this drug class. Body weight and
body composition changes have also been assessed in patients with
Pso or PsA while receiving anti-TNFα treatment. In a longitudi-
nal study of 24 weeks duration, 40 patients with Pso or PsA were
treated by infliximab or etanercept, 2 TNFα inhibitors. Compared
to baseline, the results showed a significant gain in body weight in
both groups (+2.6 and +2.1% in Pso and PsA, respectively), an
increase in fat mass in the Pso group (+8.5%), and in both fat mass
(+8.9%) and lean mass (+2.9%) in the PsA group (47). However,
in this study, fat distribution (android or visceral region) was not
analyzed. In a retrospective analysis of patients with chronic plaque
Pso, a body weight increment (+1.5 to +2.5 kg) was observed in
patients receiving anti-TNFα agents for 6 months, while no change
was observed for those under methotrexate. In parallel, BMI also
increased (+ 0.5 to +0.8) and about a quarter of patients had a
4–10 kg weight gain during this study (48). In addition, it has been
suggested that weight gain may be higher with etanercept than
with infliximab (49). On the contrary of TNFα inhibitors, ustek-
inumab, was not associated with weight or BMI change in patients
with Pso (50).
On the other hand, obesity may influence the therapeutic
approach and clinical response to systemic treatment in Pso or
PsA, especially, the response to anti-TNFα treatment. Indeed,
adipose tissue may alter the volume of drug distribution, and
thus limit drug efficacy (20). Since biological drugs are usually
administered at a fixed dose, a weight-adjusted dose is probably
necessary for overweight/obese patients. In this sense, beneficial
effects of weight loss on skin disease have been suggested in case
reports of Pso clearing with reduction of obesity (51). A recent
review analyzed the available literature on the biological treat-
ment response according to body weight in patients with Pso.
The conclusion was that optimal treatment response with fixed
dose biological agents was less frequent in patients with increasing
weight, especially above 100 kg (52). The same results were found
for patients with PsA. In a prospective follow-up of 135 obese
patients with PsA and 135 normal weight PsA controls, the pres-
ence of abdominal obesity was associated with an increased risk of
not achieving the minimal disease activity (MDA) (53). The same
authors demonstrated that a low-calorie diet intervention in over-
weight or obese patients with PsA was associated with a higher rate
of MDA achievement (54). Another study confirmed this relation-
ship between fat mass and clinical response in PsA in a Canadian
population of 557 patients with PsA. The authors reported a dose
response association between obesity and the probability of having
clinical response to treatment [disease modifying anti-rheumatic
drugs (DMARD) and/or TNFα inhibitor], with the patients in
the higher BMI category less likely to achieve MDA compared to
those in the lowest BMI category after adjustment for confounding
variables (55).
RELATIONSHIPS BETWEEN OBESITY, PSORIASIS, AND
PSORIATIC ARTHRITIS
There is compelling evidence suggesting that both Pso and PsA
are associated with an excess of fat tissue (8, 20) (Figure 1).
Moreover, obesity-related comorbidities accumulate in both con-
ditions, especially, CV and metabolic comorbidities, leading to an
increased CV burden. Pro-inflammatory cytokines, such as TNFα
and IL-6, and the adipokines leptin, resistin, and visfatin produced
by fat tissue are contributing and probably synergistic factors to
a pro-inflammatory state in these conditions. Both Pso and PsA
are associated with body composition changes, mainly in PsA.
One unanswered question is the timing of adipose tissue changes:
BMI and weight in early adulthood seem to predict Pso and PsA
and conversely, patients with established disease (Pso or PsA) are
characterized by excess fat mass. In other words, it remains to be
clarified whether fat mass plays a role at the beginning (or before
onset) of the disease, or whether the systemic inflammation in
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FIGURE 1 | Interrelationships between fat tissue, psoriasis (Pso), and
psoriatic arthritis (PsA) are shown. Obesity is a predisposing factor the
development of both Pso and PsA. Pso and PsA are associated with
obesity-related complications such as metabolic syndrome, dyslipidemia,
diabetes, or insulin resistance, which all enhance the cardiovascular (CV) risk.
Body composition is disturbed in Pso or PsA, especially in patients with PsA
who have an excess of abdominal adiposity, contributing to increase the risk
of metabolic syndrome and CV diseases. Adipokines may link the adipose
tissue to the obesity-related complications of Pso and PsA: altered circulating
levels of the adipokines leptin, adiponectin, visfatin, resistin omentin, and
retinol-binding protein-4 (RBP-4) have been found in patients with Pso or PsA.
Leptin has pro-inflammatory effects and may contribute to skin and joint
inflammation. Adiponectin promotes insulin sensitivity and its reduced level in
Pso may drive insulin resistance and may lead to impaired cardiac and
vascular protective effects, thus contributing to the CV risk. In addition, the
excess of adipose tissue in Pso and PsA may compromise the therapeutic
response to biological agents in Pso and PsA. Finally, anti-TNFα agents have
been associated with weight gain in patients with Pso or PsA.
these chronic conditions may govern weight modification and fat
redistribution.
The adipokines produced by adipose tissue in the context of
Pso or PsA have a wide range of targets and consequences. An
excess of fat mass results in the production of chemokines such as
monocyte chemoattractant protein-1 (MCP-1), which contributes
to increasing resident macrophages in fat tissue. This in turn
may perpetuate the pro-inflammatory state (6). Adipose tissue
may produce pro-angiogenic factors such as vascular endothelial
growth factor, contributing to the skin and synovial pathogenesis
in Pso and PsA, respectively (8). Adiponectin is believed to have
anti-inflammatory effects (at least its low molecular weight frac-
tion). Low serum levels of (total) adiponectin have been observed
in Pso (but not in PsA) and a reduced level of adiponectin is
associated with insulin resistance an impaired cardiac and vascu-
lar protective effects. These reduced adiponectin levels may thus
contribute to the CV risk in Pso. According to cross-sectional
studies and even after adjustment for sex and BMI, an excess of
leptin characterized both Pso and PsA patients, contributing to
the obesity-related inflammation. Leptin has also pro-angiogenic
activities and is involved in the induction of endothelial dysfunc-
tion. Therefore, high leptin levels may accelerate atherosclerosis in
patients with Pso and PsA. The high levels of visfatin and resistin
also participate in the pro-inflammatory state and insulin resis-
tance in Pso and PsA. More data are needed to fully understand
the role of RBP-4 and omentin in Pso and PsA and their influence
on CV comorbidities. In addition, there is no available data on the
different adiponectin fractions in Pso or PsA. Collectively, these
results strongly support the fact that obesity and fat tissue have the
potential to initiate and drive many of the known inflammatory
mechanisms underlying the pathogenesis of Pso and PsA and also
their cardio-metabolic complications. Moreover, the importance
of adipose tissue seems to be greater in PsA than in Pso and greater
than in other inflammatory conditions. Indeed, a recent report
showed that patients with PsA had the highest BMI compared to
patients with Pso, RA, or the general population (56).
CONCLUSION
The relationships between obesity, Pso, and PsA represent a chal-
lenging issue to be addressed. Obesity may determine both Pso and
PsA development. Pso and PsA share a common serum adipokine
profile, body composition changes, and cardio-metabolic compli-
cations,also with similar clinical outcomes such as the likelihood to
achieve reduced disease activity during treatment with DMARDs
and/or biologics. Obesity in both Pso and PsA is thus an impor-
tant concern that must be adequately recognized and managed
by clinicians. In addition, obesity-related complications are more
prevalent in patients with PsA compared to Pso patients with-
out arthritis. Thus, clinicians must carefully assess adipose tissue
in patients with Pso and especially in those with concomitant
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arthritis, by evaluating weight, BMI, and the other clinical indices
of visceral adiposity, in order to estimate the CV risk in these
patients. Accordingly, weight loss should also be obtained in over-
weight/obese patients. This should contribute to reducing the CV
risk, improving therapeutic response to DMARDs and/or biolog-
ics, improving mobility and thus physical activity, and ultimately
should improve the long term prognosis of these patients.
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